Yet, recent advances in understanding the molecular drivers of HCC have led to a new era of molecular targeting agents such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (MTOR) inhibitors [11,12]. This evidence concerns the gene MTOR and hepatocellular carcinoma.